Biotech Values

[dia76ca]

Thanks for the intelligent post biomaven0.

It is of course the second line NSCLC study which is of most interest. They(under Dr. Garnick's influence)designed it as they would a registrational trial as they have all(including Garnick) expressed the possibility of an application for Accelerated Approval if the results are outstanding. Some time ago it was announced that the Doce alone arm has achieved a MOS of less than 6 months. We are awaiting the MOS from the low dose Bavi/Doce arm and the high dose Bavi/Doce arm. Those who follow this trial closely think these arms MOS may already exceed 12 months.

The MOA is very interesting but it is the MOS data that is most important. We should get that information in the next few weeks or months...the longer wait the better both for patients and investors!